News

Takeda announced that it will globally discontinue two of its hemophilia A treatments: Hemofil M, a plasma-derived therapy, and Recombinate, the first…

The U.S. FDA has approved Sanofi’s Qfitlia (fitusiran), the first antithrombin-lowering therapy for routine prophylaxis to prevent or reduce the frequency of…

LA Kelley Communications’ flagship book Raising a Child with Hemophilia is available to download free as a PDF from its website. First…

More than 350 people and 10 Milwaukee-area bars and restaurants attended GLHF’s premier fundraising event, Milwaukee’s Best Bloody, on April 13. Our…

We need your help! Contact your representatives today! On April 1, the US Department of Health and Human Services (HHS) issued termination…

Powered by the Hemophilia Outreach Center Beyond the Bleeds, a Podcast powered by the Hemophilia Outreach Center, and hosted by heather Hansen…

Save-the-date for our 2025 Unite for Bleeding Disorders Walk at the Milwaukee County Zoo, Sunday September 27, 2025!  Register today, raise $25…

Whether you’re new to the bleeding disorders community or have been a part of it for years, GLHF’s Wisconsin Bleeding Disorders Conference…

NBDF Expands Health Access Initiatives Through Strategic Department Evolution Foundation Continues Mission Alignment with Enhanced Focus on Health Access, and Innovation to Better Serve Growing…

A Message from Phil Gattone, NBDF President and CEO Major restructuring at HHS has placed nearly all CDC Blood Disorders Division staff…

This year’s World Hemophilia Day, which was held April 17, focused on “Access for All: Women and Girls Bleed Too” — tackling…

Every year the Neil Frick Resource Center (NFRC) (formerly HANDI) assembles a list of post-secondary educational scholarships that are available to students…

A newly published journal article examined current practices of HTCs for screening and assessing bone health in people with hemophilia and von…

The FDA has approved Sanofi’s Qfitlia™ (fitusiran), a new subcutaneous therapy for people with hemophilia A or B, with or without inhibitors….

“My Life, Our Future” (MLOF) is a collaborative effort that seeks to advance understanding of hemophilia by developing the MLOF Research Repository, a scientific resource….

Opening up about insurance issues, loneliness, and other challenges can benefit you and others in the bleeding disorders community. Here are three…

Earlier this week, the Trump Administration announced drastic changes and reductions to the federal health programs that support the bleeding disorders community….

Less than a year after FDA approval, Beqvez, a gene therapy for hemophilia B, has been discontinued. Manufactured by Pfizer, the one-time…

“Voices for Policy Change” is an on-line resource designed to educate, empower and mobilize on important legislative issues related to bleeding disorders…

Read Hemophilia Federation of America’s excellent “Word from Washington” about how new policies can affect you and overage for your medical care….

by: Laurie Kelley March is hemophilia awareness month and the recent upheaval over leadership in this country has me thinking about leadership…

From Vision to Victory: BD SUMHAC’s Year-in-Review Authored by: The BD SUMHAC Team Download the summary of the Bleeding Disorders Substance Use…

First published in 1990, this sixth edition is updated to include new medical treatments, resources and up-to-date advice from parents. Stay tuned…

In a surprising development, Pfizer has discontinued Beqvez™, their hemophilia B gene therapy, despite FDA approval just last spring. The company cited…